To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
6 Current news of Janssen-Cilagrss
The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).On 2 September 2011, Janssen-Cilag International NV ...
Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing ...
Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing ...
Basilea Pharmaceutica Ltd. announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI). The sponsor ...
The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) showing efficacy in patients with NNRTI-resistant HIV. Also known as TMC125, ...
Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by its license partner Janssen-Cilag International NV, a Johnson & Johnson company. This submission is for the use of ceftobiprole in the ...